OMER - Omeros Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

547.8M

Cash

230.3M

Avg Qtr Burn

-35.4M

Short % of Float

23.27%

Insider Ownership

4.45%

Institutional Own.

44.14%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OMIDRIA (phenylephrine and ketorolac intraocular solution) Details Eye disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narsoplimab (OMS721) (MASP-2 inhibitor, lectin pathway) Details Hematopoietic cell transplantation	BLA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OMS906 Details Blood disorder, Paroxysmal nocturnal hemoglobinuria	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OMS405 (PPARγ agonist) Details Addiction	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OMS1029 (MASP-2) Details Lectin pathway disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OMS527 (PDE7 inhibitor) Details Movement disorder, Levodopa-induced dyskinesia associated with Parkinson’s disease, Cocaine use disorder, Addiction	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, Diabetic macular edema, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, IgA nephropathy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Blood disorder, Rare diseases	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.